Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001437749-23-016899
Filing Date
2023-06-07
Accepted
2023-06-07 17:00:21
Documents
20

Document Format Files

Seq Description Document Type Size
1 FORM DEFA14A mbrx20230606_defa14a.htm DEFA14A 32780
2 a01.jpg GRAPHIC 291829
3 a02.jpg GRAPHIC 223060
4 a03.jpg GRAPHIC 249245
5 a04.jpg GRAPHIC 239749
6 a05.jpg GRAPHIC 248320
7 a06.jpg GRAPHIC 295351
8 a07.jpg GRAPHIC 180633
9 a08.jpg GRAPHIC 251473
10 a09.jpg GRAPHIC 181200
11 a10.jpg GRAPHIC 286939
12 a11.jpg GRAPHIC 306139
13 a12.jpg GRAPHIC 217813
14 a13.jpg GRAPHIC 235462
15 a14.jpg GRAPHIC 261549
16 a15.jpg GRAPHIC 176792
17 a16.jpg GRAPHIC 170804
18 a17.jpg GRAPHIC 169739
19 a18.jpg GRAPHIC 270108
20 a19.jpg GRAPHIC 257077
  Complete submission text file 0001437749-23-016899.txt   6248594
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671999 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37758 | Film No.: 23999710
SIC: 2834 Pharmaceutical Preparations